“A prospective, randomized and double blind once-monthly oral Ibandronate and Risedronate in post-menopausal osteoporosis leprosy patients”, Int J of Biomed & Adv Res, vol. 8, no. 11, pp. 407–415, Nov. 2017, doi: 10.7439/ijbar.v8i11.4474.